Table 4.

Etanercept Biosimilar Switching Discontinuations and ADEs^48-50

Author (Year)	Injection Site Reaction n/N (%)	ADA Development n/N (%)	Discontinuation, Any n/N (%)	Discontinuation, ADE n/N (%)	Discontinuation, Lack of Efficacy n/N (%)
Double-blinded studies
Griffiths et al. (2017)a,48	-	0/100b (0.0) 1/96 (1.0)c	11/100 (11.0)b 5/96 (5.2)c	2/100 (2.0)b 5/96 (5.2)c	2/100 (2.0)b -
Gerdes et al. (2017)49	72/196 (36.7)	0/196 (0.0)	-	6/196 (3.1)	-
Open-label studies
Emery et al. (2017)50	0/119 (0.0)	1/119 (0.8)	6/119 (5.0)	2/119 (1.7)	-

^aResults reported after second treatment period.

^bPatients receiving GP2015 for period 1 then switched to etanercept→GP2015→etanercept, which continued into extension.

^cPatients receiving etanercept for period 1 then switched to GP2015→etanercept→GP2015, which continued into extension.

ADA = antidrug antibody; ADE = adverse drug event.